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Multi-omics characterization of a 
diet-induced obese model of non-
alcoholic steatohepatitis
Helene M. Ægidius1, Sanne S. Veidal1, Michael feigh1, philip Hallenborg2, Michele puglia2, 
tune H. pers3, niels Vrang1, Jacob Jelsing1, Birgitte R. Kornum4, Blagoy Blagoev2 & 
Kristoffer T. G. Rigbolt1*
to improve the understanding of the complex biological processes underlying the development of 
non-alcoholic steatohepatitis (nASH), a multi-omics approach combining bulk RnA-sequencing based 
transcriptomics, quantitative proteomics and single-cell RnA-sequencing was used to characterize 
tissue biopsies from histologically validated diet-induced obese (Dio) nASH mice compared to 
chow-fed controls. Bulk RnA-sequencing and proteomics showed a clear distinction between 
phenotypes and a good correspondence between mRnA and protein level regulations, apart from 
specific regulatory events discovered by each technology. Transcriptomics-based gene set enrichment 
analysis revealed changes associated with key clinical manifestations of nASH, including impaired 
lipid metabolism, increased extracellular matrix formation/remodeling and pro-inflammatory 
responses, whereas proteomics-based gene set enrichment analysis pinpointed metabolic pathway 
perturbations. Integration with single-cell RNA-sequencing data identified key regulated cell types 
involved in development of nASH demonstrating the cellular heterogeneity and complexity of nASH 
pathogenesis.
Non-alcoholic fatty liver disease (NALFD) comprises a wide spectrum of liver diseases ranging from typically 
benign steatosis to non-alcoholic steatohepatitis (NASH), with or without fibrosis, that can progress into cirrho-
sis, hepatocellular carcinoma and ultimately end-stage liver disease1–3. The development of NASH is driven by 
complex and dynamic molecular mechanisms, implicating multiple parallel signalling pathways. However, the 
interplay between these different clinical and molecular manifestations linked to progression of NAFLD into 
NASH is not fully understood. Currently, no pharmacological therapies for NASH exist, however lifestyle modi-
fications have shown to be efficacious for NASH resolution4. There are no early diagnostic endpoints known, and 
since hepatic steatosis and fibrosis can present itself as asymptomatic there is an unmet need to better understand 
the etiology and pathogenesis of NASH. Accordingly, several rodent models mimicking pathological features 
of NASH have been developed to accommodate this5. Due to the distinct hepatic features of NASH, histologi-
cal techniques based on qualitative scoring systems6,7 and  quantitative image analysis have been developed for 
research applications. Omics-based strategies have been instrumental for hypothesis-free analysis of molecular 
changes in NASH. For example, genome-wide association studies have identified several loci with variants show-
ing increased risk of NAFLD and NASH development8–11 or protection from more aggressive liver pathologies12. 
Furthermore, transcriptomics has been successful in identifying novel regulatory mechanism in NASH patho-
genesis13–17. Despite the value of transcriptomics, these approaches will not always reflect the actual abundance at 
the protein level of a given the specific gene product in the cell18 or extracellular space/surrounding body fluids19. 
Quantitative proteomics has successfully been used for these purposes, uncovering biomarkers and hormones 
associated with NASH16,17,20,21. Recent advances in the field of mass spectrometry has allowed the utilization of 
proteomics in a more high-throughput setting with an increased depth of the analysis, further increasing the 
applicability of this technology for comprehensive comparative studies of global protein abundance across many 
experimental conditions, cell lines or tissues22–24. The development of new technologies providing full genome 
characterization of thousands of individual cells allowing transcriptomics analysis at the single-cell level has 
1Gubra, Hørsholm Kongevej 11B, Hørsholm, Denmark. 2Department of Biochemistry and Molecular Biology, 
University of Southern Denmark, Odense, Denmark. 3Novo Nordisk Foundation Center for Basic Metabolic Research, 
University of Copenhagen, Copenhagen, Denmark. 4Department of Neuroscience, University of Copenhagen, 
Copenhagen, Denmark. *email: kri@gubra.dk
open
2Scientific RepoRtS |         (2020) 10:1148  | https://doi.org/10.1038/s41598-020-58059-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
revolutionized the level of resolution and depth of physiological characterization attainable, resulting in a highly 
detailed profiling of cell types, often identifying hitherto unknown cell subtypes25–27.
To provide further insight into the complex molecular changes in fibrotic NASH, we applied a multi-omics 
approach, combining bulk RNA sequencing (RNA-seq) based transcriptomics, quantitative proteomics and 
single-cell RNA sequencing (scRNA-seq). The detailed characterization of the molecular signature of liver biop-
sies from diet-induced obese (DIO) NASH mice fed the AMLN diet expands our understanding of the numerous 
and intricate regulatory events underlying development of NASH.
Results
Histological validation of Diet-induced obesity mouse model of nASH. Clinical hallmarks of 
NASH were evident after 36 weeks of ALMN diet feeding as revealed by increased steatosis and inflammation, 
but not hepatocyte ballooning (Fig. 1A,B). Scoring of fibrosis stage substantiated the fibrotic phenotype of DIO-
NASH mice (Fig. 1B). Histopathological analyses were supported by quantitative image analysis of liver lipid, 
collagen 1a1, α-SMA, and galactin-3 content, all being significantly upregulated in the DIO NASH model versus 
chow control (p < 0.001, p = 0.042, p < 0.001, p < 0.001, Fig. 1C). DIO-NASH mice showed significantly increased 
whole body and liver weight (40.8 ± 1.435 g, 2.99 ± 0.29 g, n = 4) compared to chow controls (29.86 ± 0.403, 
1.12 ± 0.02 g, p < 0.001, p < 0.001, n = 5, Fig. 1C).
characterization of changes in the liver transcriptome and proteome of Dio-nASH mice. 
Quantitative transcriptome and proteome analysis provided deep profiling of the molecular changes in the livers 
of DIO-NASH mice, identifying a total of 14,675 genes and 5,968 proteins. The hepatic transcriptome signature 
of DIO-NASH vs. chow-fed animals showed widespread regulation of genes with well-established association to 
NASH development with particularly large impact on prototypical fibrosis and monocyte recruitment associated 
genes14 (Fig. 2A). Quantitative proteomics and transcriptomics both showed increased expression of the standard 
NASH markers like Col1a1, Acta2 (α-SMA), and Lgals3 (Galactin-3/Mac2) in DIO-NASH compared to chow 
controls (transcriptomics: p < 0.001, p = 0.01, p < 0.001, Fig. 2B).
Principle component analysis (PCA) of RNA-seq data showed a clear distinction between groups reflecting 
the pronounced hepatic transcriptome changes in DIO-NASH mice vs. chow controls (Fig. 2C). Similarly, PCA 
of the proteomics data allowed for a separation of the mouse models, however, less distinct compared to mRNA 
(Fig. 2D). Of the 5,968 identified proteins, it was possible to match the majority to their corresponding gene in 
the RNA-seq dataset (Fig. 2E). Differential expression analysis identified 6,725 gene regulations and 375 protein 
regulations (5% FDR). Among the 375 regulated proteins, 241 were shared between the two datasets, while 134 
were only identified as regulated in the proteomics data, suggesting widespread post-transcriptional regulation. 
Of the 241 shared regulations, 192 showed concordant directional changes at both protein and mRNA level. 14 
genes were significantly increased at mRNA level but decreased at protein level, while 35 genes were significantly 
decreased at mRNA level but increased at protein level. Thus, a generally good correspondence between the 
mRNA expression and protein abundance profile was observed, albeit with clear indications of protein level spe-
cific regulatory events (Fig. 2F).
Identification of physiological events globally regulated in DIO-NASH mice.  The underlying 
physiological changes were explored further by gene set enrichment analysis. Comparable perturbations were 
observed for many top-level pathways (Fig. 3A). Pathways with well-established association to NASH pathogen-
esis were significantly perturbed on both mRNA and protein level, including Immune System, Metabolism and 
Extracellular matrix organization. Progression of NAFLD into NASH is associated with inflammation and liver 
cell damage. Notably, we observed an activation of all major aspects of the innate- and adaptive immune system, 
including upregulation of genes in pathways associated with the Toll-receptor Cascade, the Complement system, 
MHC II antigen presentation, T- and B-cell receptor activation and monocyte recruitment on mRNA level (see 
Fig. 3B). In contrast, protein regulations were more pathway specific with the strongest signal for processes asso-
ciated with antigen processing.
As the liver is a pivotal metabolic organ, alterations of hepatic metabolism are critical to the development 
of liver disease. Accordingly, gene and protein perturbations related to macromolecule metabolism were pre-
dominantly related to metabolism of lipids and carbohydrates (Fig. 4A). In this pathway, Fahd1, Sdha, Ndufa13 
and Atp5b were differentially expressed only in the proteomics dataset (p = 0.03, p = 0.006, p = 0.04, p = 0,004, 
Fig. 4B). As lipoproteins are the main carrier by which lipids are distributed in the body, the metabolism of lipo-
proteins is believed to play a key role in dyslipidaemia observed in NASH28,29. Accordingly, lipoprotein assembly, 
remodelling and clearance pathways were significantly perturbed on both mRNA and protein level (Fig. 4C). 
However, several genes in this pathway were differentially expressed only in the proteomics dataset, includ-
ing critical factors such as Apoe, Apoa2, Apoc1 and P4hb (p = 0.005, p = 0.004, p = 0.003, p = 0.003, Fig. 4D). 
Interestingly, only Apoa2 and Apoc1 were downregulated on mRNA level, with no change in the expression of 
Apoe and P4hb.
Hepatic fibrosis resulting from accumulation of extracellular matrix proteins produced by activated hepatic 
stellate cells plays an important role in disease progression of NASH2,30. Hence, the Extracellular matrix organ-
ization pathway was significantly upregulated on both mRNA and protein level, however, with relatively few 
differentially expressed proteins. Consequently, detailed analysis of Extracellular matrix organization associated 
pathways showed no significant perturbation on protein level, whereas high degree of perturbation was observed 
for all pathways on mRNA level (Fig. 4E). mRNA expression of collagen, a major constituent of extracellular 
matrix, was increased in DIO-NASH mice compared to chow control, while the increase on protein levels was not 
statistically significant (p < 0.001, p < 0.001, p < 0.001, p < 0.001, Fig. 4F).
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Collectively, the pathway analysis validated the perturbation of NASH-associated pathways on mRNA level 
and furthermore identified several specific physiological processes that only could be detected by protein level 
analysis.
Figure 1. Histological characterization of DIO-NASH model – validation of NASH pathology. 
(A) Representative images of Hematoxylin & Eosin (H&E) and Pico-Sirius Red (PR) stainings, and 
immunohistochemical stainings of collagen 1a1, α-SMA and galectin-3. (B) Histological assessment 
of steatosis, inflammation and NALFD activity score (H&E) and fibrosis stage (PR). (C) Quantitative 
histochemical assessment of liver lipid content (p < 0.001) (H&E), collagen 1a1 (p = 0.042), α-SMA (p < 0.001), 
galactin-3 positive cells (p < 0.001) (% of fractional area), whole body weight (p < 0.001) and liver weight 
(p < 0.001). In panel C, data are expressed as the mean of n = 4-5 ± SEM. A student’s t-test was used. *p < 0.05, 
**p < 0.01, ***p < 0. 001 vs. CHOW.
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Single-cell sequencing reveals cell specific regulations involved in NASH pathogenesis.  To 
resolve the cellular heterogeneity of NASH development and physiological response identified by the pathway 
analysis, cell types involved in NASH pathogenesis were identified by single-cell transcriptomics. Using the 10x 
Genomics Chromium technology, the transcriptome of DIO-NASH and chow liver biopsies were profiled by 
scRNA-seq. All major cell types, including B cells, dendritic cells, dividing cells, endothelial cells, epithelial cells, 
erythrocytes, granulocytes, hepatocytes, NK cells, macrophages, stellate cells and T cells were identified in liver 
samples from both DIO-NASH mice and chow controls (Fig. 5A,B). Based on expression of subtype-specific 
marker genes, several cell types were resolved into subtypes, resulting in a total of 23 clusters corresponding to 
distinct cell populations. These included four endothelial subtypes, five macrophage subtypes, two T cell subtypes 
and four dendritic cell subtypes (Fig. 5C).
Figure 2. Model validation using transcriptomics and proteomics. (A) mRNA expression of genes (prototypical 
gene nomenclature) associated with NASH development in chow and DIO-NASH mice. (B) mRNA expression 
and protein abundance of histological markers Col1a1, α-SMA and Lgals3. (C,D) Principal component 
analysis (PCA) of the 500 most variable genes (C) and proteins (D). (E) Venn diagram showing total number of 
identified genes (red) and proteins (blue), the total amount of differentially expressed (DE) genes and proteins 
and the overlap between total number of identified and DE genes and proteins. (F) Correspondence between 
mRNA and protein expression. Black dots represent common differentially expressed genes and proteins 
(adjusted p < 0.05). In panel (A), data is presented as standardized relative expression. In panel (B), data is 
presented as fold change of mean of n = 4-5 ± SEM (DIO-NASH/CHOW) (relative expression). * adjusted 
p < 0.05, ** adjusted p < 0.01, *** adjusted p < 0. 001 vs. CHOW. In panel (F), data is presented as log2 fold 
change (DIO-NASH/CHOW). For all panels (A–F), n = 4-5.
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The four endothelial cells clusters are representing liver sinusoidal endothelial cells, periportal and pericen-
tral endothelial cells and a population of unknown origin31. Liver sinusoidal endothelial cells showed enriched 
expression of Gpr182, Fcgr2b, Stab2 and Cd36. Periportal endothelial cells showed enriched expression of 
Tm4sf1, Efnb1, Id1 and F8. Pericentral endothelial cells showed enriched expression of Pecam1, Rspo3, Cdh13, 
Thbd and Wnt2. The last endothelial cell population showed high expression of Gpr128, Fcgr2b and Cd36 sug-
gesting that these might also be sinusoidal cells. This cell population was almost exclusively found in NASH livers 
and showed increased expression of MHC class II molecules suggesting that these cells have an immunogenic 
expression profile. Five Cd68+ macrophage populations were identified with the largest being monocyte-derived 
macrophages, but also resident Kupffer cells were prevalent. One macrophage cluster had a transcriptomic profile 
resembling both monocytes-derived macrophages and Kupffer cells. These cells showed enriched expression of 
Trem2 and Cd9.
To investigate hepatic cell types associated with signalling pathway perturbations in DIO-NASH mice, 
subtype-specific marker genes from the single-cell expression atlas were cross-referenced to regulations from the 
proteomic and transcriptomic datasets. Based on the number of genes regulated, the major cell types perturbed 
in our DIO-NASH model were hepatocytes, epithelial cells, stellate cells, macrophages and sub-populations of T 
cells and dendritic cells (Fig. 5D). Interestingly, most of the hepatocyte and epithelial marker genes were down-
regulated in DIO-NASH, whereas most of the macrophage and stellate cell marker genes were upregulated in 
accordance with increased inflammation and fibrosis. Many stellate cell specific changes in mRNA level was 
observed supporting a highly perturbed Extracellular matrix organization pathway (Fig. 5D).
To assign cell-type-specificity to regulations related to the histological manifestations of NASH, the distribu-
tion of gene expression of histological markers, Col1a1, Acta2 and Lgals3 was assessed (Fig. 6). Col1a1 and Acta2 
expression were exclusively expressed in DIO-NASH stellate cells, whereas Lgals3 was expressed by most of the 
immune cell populations across both experimental groups.
To further characterize cell-specific regulations, significantly regulated marker genes for hepatocytes, mac-
rophages and stellate cells were extracted, as they have been shown to be critical drivers of NASH pathogenesis 
(Fig. 6). In hepatocytes, gene markers were primarily associated with metabolic processes of the liver, especially 
lipid metabolism, as exemplified by a strong enrichment of Scd1, Idh1, Acaa1b, Rbp4, Serpina12 and Krt8, with 
the latter also showing enriched expression in epithelial cells. However, expression of lipid transporters, such as 
Cd36, were mainly present in endothelial cells and macrophages. Macrophages showed a clear enrichment of 
genes involved in cytokine signalling, albeit with several genes also showing less, but relevant, expression in other 
cell types. In contrast, the population of stellate cells was highly distinct with cell-type specific marker genes being 
essentially exclusively expressed in these cells, as evident for genes such as Adamts2, Lumican (Lum), Timp2, 
Mmp2 and Decorin (Dcn), all of which are involved in extracellular matrix production and remodelling. Overall, 
cross-referencing bulk RNA-seq and proteomics with scRNAseq allowed for assignment of major cell types to 
regulatory events and identified several key cell-specific regulations.
Figure 3. Global pathway analysis of transcriptomic and proteomic data. (A) Global transcriptome and 
proteome perturbations according to enrichment of individual gene sets in the Reactome pathway database 
indicating perturbed pathways in DIO-NASH vs. CHOW. (B) Transcriptome and proteome perturbations of 
Immune system sub-pathways. In panels (A,B), perturbed pathways are ranked according to level of statistical 
significance (mRNA only). The degree of perturbation for each pathway is normalized and presented as the 
relative regulation of the maximum p-value for each dataset.
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Figure 4. Metabolic and fibrotic pathway profiling. (A) Transcriptome and proteome perturbations of 
Metabolism sub-pathways. (B) mRNA expression and protein abundance of genes in the Metabolism pathway 
that are differentially expressed only on protein level. (C) Transcriptome and proteome perturbations of Transport 
of small molecules sub-pathways. (D) mRNA expression and protein abundance of genes in the Transport of 
small molecules pathway that are differentially expressed only on protein level. (E) Transcriptome and proteome 
perturbations of Extracellular matrix organisation sub-pathways. (F) mRNA and protein expression of genes 
in Extracellular matrix organisation pathway that are differentially expressed only on mRNA level. In panels 
(A,C,E), perturbed pathways are ranked according to level of statistical significance (mRNA only). The degree of 
perturbation for each pathway is normalized and presented as the relative regulation of the maximum p-value for 
each dataset. In panels (B,D,E), data is presented as the fold change of the mean of n = 4–5 ± SEM (DIO-NASH/
CHOW) (relative expression). * adjusted p < 0.05, ** adjusted p < 0.01, *** adjusted p < 0. 001 vs. CHOW in 
RNAseq data. # adjusted p < 0.05, ## adjusted p < 0.01, ### adjusted p < 0. 001 vs. CHOW in proteomics data.
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Discussion
In the present study, we performed a comprehensive characterization of the molecular signature of a histologically 
validated diet-induced model of NASH. As previously reported32–37, the AMLN DIO-NASH model exhibits key 
hallmarks of NASH pathogenesis; steatosis, inflammation and moderate fibrosis. As in human liver pathologies, 
DIO-NASH mice are characterized by a large variation in disease progression and thus a careful validation of the 
phenotype is a prerequisite for the validity of omics data obtained from NASH animal cohorts. Histopathological 
scoring recapitulated clinical criteria for diagnosing fibrosing NASH6,38, albeit without ballooning degenera-
tion. Quantitative histological assessment showed significant intrahepatic lipid accumulation, inflammation 
and collagen deposition in DIO-NASH compared to chow animals. We demonstrate widespread perturbations 
of the hepatic transcriptome and proteome, with overall good correspondence at the mRNA and protein level. 
Furthermore, combining bulk RNA-seq, quantitative proteomics and scRNA-seq constitute a powerful approach 
for dissecting the complex hepatic regulations associated with NASH. Notably, it provided us with a cell type 
Figure 5. Discovering cell-specific changes in protein and gene levels of DIO-NASH mice. (A) UMAP 
projection of 6888 cells from CHOW and DIO-NASH livers. Each point represents a single cell. Cells that 
show similar transcriptomic profile are grouped by colour based on unsupervised clustering. 23 different 
cell populations were identified. Cell type identity was assigned by matching canonical markers with gene 
expression profile of each cluster. (B) UMAP projection showing how each experimental group contribute to 
each cell cluster. (C) UMAP projections showing sub-populations of endothelial cells, macrophages, T cells and 
dendritic cells. (D) Differentially expressed genes and proteins which was either up- or downregulated in DIO-
NASH has been assigned to a specific cell-type as identified by scRNAseq by cross-referencing with marker 
genes (enriched genes).
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specific pathway regulation atlas that augments the intrinsic complexity of NASH and heterogeneity of cell types 
involved in pathogenesis.
Differential expression analysis often assumes that changes in mRNA expression have biological meaning and 
induce corresponding changes in protein levels. However, moderate correlation between the proteome and tran-
scriptome have been shown repeatedly18,39. Protein abundance is highly dynamic and multiple processes contrib-
ute to the abundance of a protein; mRNA abundance, translation efficiency, and protein turnover, all of which can 
be influenced by environmental conditions40. In addition, profiling the proteome has some inherent challenges; 
detecting low-abundance molecules can be difficult due to a wide dynamic range of protein expression, inefficient 
extraction of specific protein classes and difficulties with identifying small proteins. The present study demon-
strate that transcriptomics analysis provides the most comprehensive dissection of the molecular signature of the 
DIO-NASH mouse model. However, as changes in mRNA level was not consistently accompanied by a change in 
protein level and vice versa, transcriptomic analysis alone would disregard important biological regulations. The 
explanation for the difference between identified regulations at mRNA and protein levels is likely multifactorial, 
with both biological and technological aspects contributing. Thus, a limitation of this study is the sample size that, 
combined with the variation in the animal model, could negatively impact the ability to identify differentially 
abundant proteins. The sample size could also influence the scRNAseq data preventing detection of extremely 
rare cells types, however, more influential is probably the fragility of hepatocytes leading to a loss of these cells 
during sample preparation.
Gene enrichment analysis revealed that proteome analysis was most efficient for identification of specific 
metabolic pathway perturbations, while RNA-seq was superior for characterizing regulations of immunological 
and fibrotic networks. Especially, the technical challenges associated with characterization of collagen proteins by 
mass spectrometry is worth noting since it has important clinical implications due to the slow turnover of many 
extracellular matrix proteins. We have previously shown that RNA-seq can efficiently detect reduction in expres-
sion of collagens by a panel of pharmaceutical compounds in advanced clinical trials, this is not mirrored in a 
histological reduction of liver fibrosis37. Other examples of the need for a multi-omics strategy is Rbp4 and Erlin1. 
Rbp4 is a carrier of retinol from liver into blood, which has received much attention as potential biomarker of 
NAFLD and NASH, however, the association is a matter of debate41–45. In this study, we found that the protein 
level of Rbp4 was significantly increased, whereas mRNA levels were significantly decreased in DIO-NASH mice. 
This is consistent with what previously have been found in a study including NASH patients where they showed 
increased serum Rbp4 levels43. Erlin1 is involved in regulation of cellular cholesterol homeostasis by regulation 
the SREBP signalling pathway46 and genetic variants of Erlin1 have been shown to be associated with increased 
susceptibility of hepatic steatosis and inflammation11. In this study, we found that the protein level of Erlin1 was 
significantly increased, whereas mRNA levels were significantly decreased in DIO-NASH mice.
The combined scRNA-seq and RNA-seq hepatocyte transcriptomic profile showed increased fatty acid syn-
thesis and B-oxidation. Lipids not exported into the blood as VLDL particles form lipid droplets in hepatocytes, a 
defining feature of NASH47. Accordingly, the present gene enrichment analysis identified pathway perturbations 
associated with assembly, remodelling and clearance of lipoproteins suggesting an altered lipoprotein metabolism 
in DIO-NASH mice.
NASH has repeatedly been associated with mitochondrial dysfunction48–52 and the gene enrichment analysis 
showed impaired mitochondrial function by decreased expression of genes involved in TCA cycle, respiratory 
electron transport and ATP synthesis in DIO-NASH animals. Injured hepatocytes activate proinflammatory 
Figure 6. Uncovering regulated marker genes for key cell types involved in NASH pathogenesis. Cell specific 
distribution of gene expression of histological markers, Col1a1, Acta2 and Lgals3, and significantly regulated 
marker genes for hepatocytes, macrophages and stellate cells. Dot size represents the percentage of cells in a 
cluster expressing a given gene (detection rate, % cell).
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pathways by releasing cytokines, chemokines and other inflammatory mediators53. Consistently, hepatocyte spe-
cific expression of pro-inflammatory genes was upregulated in DIO-NASH and an overall upregulation of both 
the innate and adaptive immune system was observed.
Recently, Xiong and co-workers16 published a multi omics strategy to characterize a similar DIO-NASH 
model, albeit at an earlier timepoint and presumably less severe disease stage. In accordance to our dataset, Xiong 
et al. observe that most of the hepatocyte marker genes were downregulated in DIO-NASH, whereas most of the 
macrophage and stellate cell marker genes were upregulated, consistent with an upregulation of the Extracellular 
matrix organization and Immune System pathways. This data suggest that cell-type-specific reprogramming of the 
liver cell transcriptomes is linked to NASH pathogenesis.
Taken together, the molecular signature of the DIO-NASH model is associated with impaired intrahepatic 
lipid and carbohydrate handling, enhanced immune system activity and inflammatory signalling, mitochondrial 
dysfunction and enhanced extracellular matrix production and remodelling demonstrating the multifactorial 
nature of NASH. Hence, the AMLN DIO-NASH model demonstrates a high level of concordance with molecu-
lar and clinical manifestations of human NASH. Finally, the liver single-cell atlas revealed several key cell types 
involved in NASH, demonstrating the cellular heterogeneity and complexity of NASH pathogenesis.
Methods
Animals. All animal experiments were performed with ethical approval by the Gubra ethical committee 
and conducted in accordance with internationally accepted principles for the care and use of laboratory animals 
issued by the Danish Committee for Animal Research (license no. 2013-15-2934-00784, The Animal Experiments 
Inspectorate, Denmark).
Male C57Bl/6J mice at 5 weeks of age were obtained from Janvier Labs (Le Genest Saint Isle, France) and 
housed five per cage under a 12:12 hour dark–light cycle. Animals were either fed a diet high in fat/fructose/
cholesterol (D09100301, Research Diets, New Brunswick, NJ, USA), previously described as AMLN-diet33 or 
regular rodent chow (Altromin 1324, Brogaarden, Denmark) and water. Both groups had ad libitum access to 
either the AMLN diet or rodent chow. After 36 weeks on diet animals were euthanized by heart puncture under 
1-2% isoflurane anaesthesia and the left lateral lobe was collected for further analysis. 9 animals (DIO-NASH, 
n = 4, lean chow = 5) was used for proteomics and RNA-seq. 6 animals (DIO-NASH, n = 2, lean chow = 4) were 
used for scRNA-seq.
Histology. Liver biopsies were collected from the left lateral lobe and fixed overnight in 4% paraformalde-
hyde. Liver biopsies were paraffin embedded, sectioned and stained with Hematoxylin & Eosin (Dako, Glostrup, 
Denmark), Pico-Sirius red (PSR, Sigma-Aldrich, Brøndby, Denmark), anti-type-1-collagen (Sourthern Biotech), 
anti-alfa-SMA (Abcam, Cambridge, UK) or anti-Galectin-3 (Biolegend, San Diego, CA) as described previ-
ously36,37. The NAS and fibrosis staging system outlined by Kleiner et al.6 was applied by experienced histopathol-
ogists to score liver biopsies for steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis. Quantitative 
image analysis of stained liver sections were analyzed using the digital imaging software (Visiomorph; 
Visiopharm, Hørsholm, Denmark)36,37. Histo-chemical positive staining areas were expressed relative (%) to the 
total tissue sectional area (fractional area). Quantitative histological data were analyzed using GraphPad Prism 
v.7.04 software (GraphPad, LaJolla, CA), and results are shown as mean of n = 4–5 ± SEM. A students t-test was 
performed for quantitative histology data. All histological assessments were performed by a expert pathologist 
blinded to the experimental groups.
RnA sequencing. Bulk liver transcriptome analysis was performed by RNA-seq of RNA extracts from liver 
biopsy samples (15 mg of fresh tissue). RNA sequencing libraries were prepared using the NEBNext Ultra II 
Directional RNA Library Prep Kit and sequenced (75 base-pair, single end reads) on a NextSeq 500 (Illumina, San 
Diego, CA, USA) with a NextSeq 500/550 High Output Kit V2 (Illumina, San Diego, CA). Reads were mapped 
to the GRCm38 v89 Ensembl Mus musculus genome using STAR v.2.5.2a (Dobin et al., 2013). The R-package 
DESeq. 2 v.1.18.1 was used for differential expression analysis (Love et al., 2014). P-values were adjusted using 
Benjamini-Hochberg method and genes with adjusted p < 0.05 was considered statistically significantly regu-
lated. The Reactome pathway database54 was used as gene annotation for gene enrichment analysis using the R 
package PIANO v.1.18.155, with the Stouffer method and Benjamini-Hochberg adjusted p-values.
proteomics Spectral library generation and Data Dependent Acquisition (DDA). For quantitative 
comparison of the liver proteomes from CHOW and DIO-NASH mice, approximately 50 mg of liver tissue was 
homogenized and sonicated in denaturing buffer (8 M guanidine hydrochloride (GuHCl) in 25 mM ammonium 
bicarbonate). The protein samples were reduced with 2 mM DTT, alkylated with 11 mM chloracetamide, diluted 
with 25 mM ammonium bicarbonate to 2 M GuHCl and proteolytically digested with LysC (1:100) for 2 hours at 
room temperature. Following a dilution to 1 M GuHCl, the samples were digested with trypsin (1:100) overnight 
at room temperature. After acidification, peptides were desalted and lyophilized. A fraction (20 ug) of solubilized 
trypsin-digested peptides from all replica and condition were combined (200 ug total) and used to generate the 
spectral library for the following LC-MS/MS Data Independent Acquisition (DIA). The total peptide mixture was 
fractionated using high pH reverse phase chromatography on an Ultimate3000 HPLC system (Thermo Fisher 
Scientific) using a 10 cm long ACQUITY CSH C18 1.7 µm column (Waters) and a linear gradient of acetonitrile in 
water (pH 9) at a flow-rate of 5 µL/min for a total of 100 min. A total of 36 subfractions were collected and concat-
enated by combining subfraction #1 with #13 and #25, subfraction #2 with #14 and #26, etc. until obtaining a total 
of 12 fractions. The fractionated peptides, together with the input flow through (FT) fraction were processed as 
previously described23. Briefly, they were vacuum dried in a speed-vac and resolubilized in 7 μL of 0.5% acetic acid 
(AA) in water and used for the nanoLC-MS/MS analysis on a Q Exactive HF-X mass spectrometer coupled with 
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an EASY-nLC 1000 ultra-high-pressure system (Thermo Fisher Scientific). Low pH reverse phase chromatogra-
phy was performed on a 22 cm fused silica column with an inner diameter of 75 µm packed in house with C18 
resin (1.9-µm beads, Reprosil, Dr. Maisch). Peptides were separated using a linear gradient of acetonitrile in water 
and 0.5% acetic acid (pH < 3) at a flow-rate of 0.25 µL/min for 110 min, followed by a washing phase of 10 min 
for a total of 120 min. The Q Exactive HF-X mass spectrometer was operated in positive polarity mode with spray 
voltage set to 2.3 kV and heated capillary temperature at 275 °C. MS data were acquired using a Data Dependent 
Acquisition (DDA) method switching between full scan events and the top 12 MS/MS scans. An automatic gain 
control (AGC) target value was set to 3 × 106 and resolution was set to 60,000 for full MS scan events with a 
scan range of 300–1,700 m/z and a maximum ion injection time (IT) of 15 ms. Precursors were fragmented by 
higher-energy collisional dissociation (HCD) with a normalized collisional energy (NCE) of 28%. MS/MS scans 
were acquired with a resolution of 30,000, maximum IT of 45 ms, 1.2 m/z isolation window. Repeat sequencing 
of peptides was prevented by setting the dynamic exclusion window to 60 s. The obtained Thermo raw files (12 
HpH-RP fractions and 1 FT) were analyzed using MaxQuant software (Version 1.5.2.8)56. The MaxQuant search 
settings for maximum missed cleavages was set to 1, peptide mass tolerance to 4.5 ppm, fragment ion tolerance to 
20 ppm and trypsin was chosen as enzyme. Variable modifications were specified to include oxidation on methio-
nine and acetylation on protein N-term. As fixed modification, carbamidomethylation of cysteine was specified. 
MaxQuant data were filtered for reverse identifications, with FDR set as 1%.
Data Independent Acquisition (DIA) and data processing. After generating the spectral library using a pool of all 
mouse liver samples and a combination of high pH fractionation and DDA approach, the remaining trypsin-digested 
peptides from all samples were analyzed independently by LC-MS/MS using a Data Independent Acquisition (DIA) 
method. Briefly, while the nanoLC system (EASY-nLC 1000, Thermo) was operating exactly as described above for 
the DDA method, the Q Exactive HF-X mass spectrometer was set to analyze the samples as described previously23 
with minor modifications. Spray voltage was set to 2.3 kV and funnel RF level at 50. Full MS mass range was set to 
300–1,300 m/z and followed by 56 PRM spectra where the target masses have been adjusted to better fit the mouse 
spectral library compared to the human cell library used previously23. In this work the first target m/z was set to 
319.5 until reaching 979.5 m/z as the last 56th target mass. Finally, normalized collision energy was set at 28%. 
DIA raw files were analyzed using Skyline v 4.2.0.18305 (MacCoss Lab software, University of Washington)57 using 
authors guidelines and settings. Library ion match tolerance was set to 5 mDa, MS/MS filtering was set to centroid 
with a 10ppm mass accuracy. Retention time filtering was set to use only scan within 10 min of library MS/MS 
identification time and to extract the Area Under the Curve (AUC) relative to the 5 most intense product ions for 
each peptide. mProphet peak scoring algorithm was trained against the decoy peptides library and used to identify 
correctly integrated target peptide with a Q-value < 0.01 (i.e. 1% FDR). Exported tables and subsequent analysis of 
data were performed in R. Differential expression analysis was performed by using two-way ANOVA on total sample 
intensity and group difference, with Benjamini and Hochberg corrections for multiple testing.
Single-cell RnA sequencing. Single-cell liver transcriptome analysis was performed by scRNA-seq of liver 
biopsy samples (25 mg fresh tissue from left lateral lobe). Tissue biopsies were digested for 30 min at 37 °C at 200 
RPM in Liberase DL (Roche, Basel). Following digestion, samples were kept on ice and the enzyme was quenched 
by adding PBS + 10% FBS. Samples were strained through a 70 µM filter and washed twice in PBS + 0.1% BSA. 
To remove red blood cells, samples were incubated for 5 min on ice with RBC lysis buffer (BioLegend, San Diego, 
CA). After incubation, samples were washed twice in PBS + 0.04% BSA and cell and viability count were assessed 
using a NucleoCounter NC-200. Samples were processed according to the 10x Genomics Single-cell 3′ v2 Reagent 
Kit user guide (10x Genomics, Pleasanton, CA). In brief, the volume of cells for specific target capture was deter-
mined for each sample. The appropriate number of cells were  loaded onto the single-cell-A-chip. Following GEM 
formation and barcoding, samples were transferred to Eppendorf tubes and reverse transcription was performed. 
Following reverse transcription, cDNA was recovered by using Recovery Agent (10x Genomics, Pleasanton, CA) 
and Silane DynaBead clean-up (Thermo Fisher, Waltham, MA). For cDNA amplification, the number of PCR 
cycles was chosen based on our target cell recovery. cDNA was amplified for 12 cycles and cleaned up using 
SPRIselect beads (Beckman, Brea, CA). Samples were run on a TapeStation (Agilent, Santa Clara, CA) to deter-
mine the cDNA concentration. Library construction was performed according to the user guide and the appro-
priate number of cycles for the sample index PCR reaction was chosen based on the cDNA concentrations. cDNA 
libraries were sequenced on a NextSeq 500 using NextSeq 500/550 High Output Kit v2.5 (150 cycles) (Illumina, 
San Diego, CA). Number of cycles were chosen based on 10x recommendations.
The sequencing data was aligned to the GRCm38 v89 Ensembl Mus musculus genome using the CellRanger (v. 
1.1.0, 10x Genomics) software. Cell Ranger uses Spliced Transcripts Alignment to a Reference (STAR) software to 
align. For the bioinformatic analysis, the quality of the data was evaluated using standard RNA-seq quality con-
trol parameters. The CellRanger (10x Genomics, Pleasanton, CA) analysis pipeline was used to generate a digital 
gene expression matrix of the data. The Seurat R package (v. 3.1.1)58 was used to filter, normalize and cluster the 
data. Selecting a biological relevant number of clusters included performing PCA, determine differential expres-
sion between neighbouring clusters, creating a K-nearest neighbour graph and perform modularity optimiza-
tion (Louvain algorithm). Differential expression between clusters was calculated using a likelihood-ratio test 
for single-cell gene expression implemented in Seurat at a family-wise error rate of 5%. Clusters were visualized 
using Uniform Manifold Approximation and Projection (UMAP). Cell identity was determined by examining the 
most enriched genes in each cluster (marker genes) and compare these with canonical marker genes of cell types 
known to be present in the liver.
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